SCHEMBL25920685

SCHEMBL25920685

CCCCN1C(=O)CSc2ccc(C(=O)O)cc21

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.66
▸ ALDH1A1 P00352 6/20 0.61
▸ L3MBTL1 Q9Y468 1/20 0.61
▸ USP2 O75604 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54
▸ POLB P06746 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ NPC1 O15118 1/20 0.48
▸ SIGMAR1 Q99720 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25920681 0.92 LMNA (0.69) LMNAALDH1A1L3MBTL1USP2TSHR
SCHEMBL10022667 0.87 LMNA (0.68) LMNAALDH1A1L3MBTL1USP2TSHR
SCHEMBL24125231 0.82 ALDH1A1 (0.61) LMNAALDH1A1L3MBTL1USP2TSHR
SCHEMBL30270516 0.80 LMNA (1.00) LMNAALDH1A1L3MBTL1USP2TSHR
SCHEMBL2636675 0.80 LMNA (1.00) LMNAALDH1A1L3MBTL1USP2TSHR
SCHEMBL31411772 0.79 LMNA (0.60) LMNAALDH1A1L3MBTL1USP2TSHR
SCHEMBL23768992 0.79 ALDH1A1 (0.71) LMNAALDH1A1NPSR1POLBSMN1; SMN2
SCHEMBL29978848 0.79 ALDH1A1 (0.71) LMNAALDH1A1NPSR1POLBSMN1; SMN2
SCHEMBL31411651 0.78 LMNA (0.59) LMNAALDH1A1L3MBTL1USP2TSHR
SCHEMBL25920688 0.75 ALDH1A1 (0.65) LMNAALDH1A1L3MBTL1USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 LMNA 4265/4885ALDH1A1 2654/4885L3MBTL1 1424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback